CN111529640A - 一种预防术后肠息肉复发的中药组合物和中药制剂 - Google Patents
一种预防术后肠息肉复发的中药组合物和中药制剂 Download PDFInfo
- Publication number
- CN111529640A CN111529640A CN202010476786.XA CN202010476786A CN111529640A CN 111529640 A CN111529640 A CN 111529640A CN 202010476786 A CN202010476786 A CN 202010476786A CN 111529640 A CN111529640 A CN 111529640A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 208000032177 Intestinal Polyps Diseases 0.000 title claims abstract description 29
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 7
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 22
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 21
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 21
- 244000197580 Poria cocos Species 0.000 claims abstract description 21
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 21
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 21
- 239000009910 sargent gloryvine Substances 0.000 claims abstract description 20
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 19
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 19
- 241000219068 Actinidia Species 0.000 claims abstract description 18
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 8
- 241000736199 Paeonia Species 0.000 claims description 14
- 241000218202 Coptis Species 0.000 claims description 11
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 241001106477 Paeoniaceae Species 0.000 claims description 9
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 9
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 7
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 31
- 208000024891 symptom Diseases 0.000 abstract description 15
- 208000037062 Polyps Diseases 0.000 abstract description 10
- 230000001575 pathological effect Effects 0.000 abstract description 6
- 208000035240 Disease Resistance Diseases 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 229940079593 drug Drugs 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 208000022131 polyp of large intestine Diseases 0.000 description 9
- 206010051589 Large intestine polyp Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000002052 colonoscopy Methods 0.000 description 3
- 238000009297 electrocoagulation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 206010060926 abdominal symptom Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000012143 endoscopic resection Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001083838 Lardizabalaceae Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000124464 Paeonia veitchii Species 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开一种预防术后肠息肉复发的中药组合物，涉及中药技术领域；所述中药组合物包括：桂枝12‑18份、茯苓12‑18份、牡丹皮7‑13份、炒桃仁7‑13份、赤芍15‑25份、黄连3‑5份、皂刺12‑18份、红藤12‑18份、藤梨根12‑18份和炒薏苡仁12‑18份。本申请的中医组合物不仅可以预防息肉的复发还能调整或逆转患者整体病态因素，使患者恢复健康体质，增强抗病能力；经临床观察，大肠息肉术后服用本申请的中药组合物可缓解症状、预防复发，疗效显著，且无明显副作用，具有良好的临床应用价值。
Description
技术领域
本发明涉及中药技术领域，具体涉及一种预防术后肠息肉复发的中药组合物和中药制剂。
背景技术
近年来，随着人们生活水平的提高，其日常生活习惯与饮食结构发生了较大的变化，大肠息肉在人们年龄的增长下发病率也在随之增高；大肠息肉作为一种在结肠黏膜表面隆起性病变的常见及多发疾病。当前在大肠息肉疾病的临床治疗中，主要是高频电切术，但因病理性质不明朗，因此无论是前期的防治与筛查，还是在内镜下切除术后的复查都只有依靠镜下检查，这不仅给患者带来了极大的身体上的痛苦，也造成了一定的经济压力，同时对于医疗资源的应用也是一种浪费。在大肠息肉内镜下切除术后，因绒毛管状腺瘤的病理类型、息肉多发且＞20mm、患者年龄大等，这都会导致大肠息肉的复发率增高；经统计发现，经肠镜切除后大肠息肉复发率仍高达44％以上。因此做好术后大肠息肉的预防复发工作对患者的身体健康的恢复与日常生活质量的改善有着积极作用。但在目前对于如何提高长期的治疗效果，减少患有肠息肉患者的复发率，减轻腹部症状或排便异常等症状并没有好的医疗手段和药物。
发明内容
为了解决上述问题，本发明针提供一种预防术后肠息肉复发的中药组合物和中药制剂
为了实现上述目的，本发明采用的技术方案之一为：一种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝10-20份、茯苓10-20份、牡丹皮5-15份、炒桃仁5-15份、赤芍10-30份、黄连2-6份、皂刺10-20份、红藤10-20份、藤梨根10-20份和炒薏苡仁10-20份。
进一步地，所述组合物包括以下组分：桂枝12-18份、茯苓12-18份、牡丹皮7-13份、炒桃仁7-13份、赤芍15-25份、黄连3-5份、皂刺12-18份、红藤12-18份、藤梨根12-18份和炒薏苡仁12-18份。
更进一步地，所述组合物包括以下组分：桂枝14-16份、茯苓14-16份、牡丹皮9-11份、炒桃仁9-11份、赤芍18-22份、黄连3-5份、皂刺14-16份、红藤14-16份、藤梨根14-16份和炒薏苡仁14-16份。
更进一步地，所述组合物包括以下组分：桂枝15份、茯苓15份、牡丹皮10份、炒桃仁10份、赤芍20份、黄连4份、皂刺15份、红藤15份、藤梨根15份和炒薏苡仁15份。
本发明采用的技术方案之二为：一种预防术后肠息肉复发的中药制剂，包括上述技术方案任一所述的中药组合物和药学上可接受的辅料。
进一步地，所述剂型为散剂、颗粒剂、丸剂、片剂或胶囊剂。
本发明的有益效果：
本发明的方剂中桂枝味辛甘性温，温通经脉而行瘀滞为君药。桃仁味苦甘平，活血化瘀，助君药以化瘀；丹皮味苦性微寒，散血祛瘀，清退瘀热；芍药味酸性微寒，养血和血，三者共为臣药；茯苓甘淡性平，健脾利湿，以助消徵之力为佐药；佐药黄连、红藤、薏苡仁清热燥湿；佐药皂角刺消肿排脓、佐药藤梨根清热消肿。全方配伍合理，立法周全，用药周到，具有活血化瘀，清热燥湿，和血消肿之功。
现代药理研究认为，桂枝具有扩张血管、抑制组胺、镇痛抗菌之效，茯苓可镇静、抑菌，牡丹皮有抑制血小板凝聚及抗炎、解热作用，赤芍有解痉、镇痛、抗炎作用，炒桃仁有显著抑制血凝作用，本申请中将诸药合用，可降低血液黏稠度，避免血小板聚集，促进纤维蛋白溶解，从而改善肠道及肠周围微循环，改善腹部不适、腹痛、腹胀、排便异常等诸症状，疗效俱佳。
本申请的中医组合物不仅可以预防息肉的复发还能通过调整、逆转患者整体病态因素，使患者恢复健康体质，增强抗病能力；经临床观察，大肠息肉术后服用本申请的中药组合物可缓解症状、预防复发，疗效显著，且无明显副作用，具有良好的临床应用价值。
除了上面所描述的目的、特征和优点之外，本发明还有其它的目的、特征和优点。下面将对本发明作进一步详细的说明。
附图说明
构成本申请的一部分的附图用来提供对本发明的进一步理解，本发明的示意性实施例及其说明用于解释本发明，并不构成对本发明的不当限定。
图1是本发明实施例的患者1术前大肠的镜检图；
图2是本发明实施例的患者1术后11个月后的大肠镜检图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅用以解释本发明，并不用于限定本发明。
本发明实施例提供的种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝10-20份、茯苓10-20份、牡丹皮5-15份、炒桃仁5-15份、赤芍10-30份、黄连2-6份、皂刺10-20份、红藤10-20份、藤梨根10-20份和炒薏苡仁10-20份。
本申请组合物的药理分析：
赤芍：为芍药科芍药属植物芍药或川赤芍的干燥根。具有清热凉血，活血祛瘀的功效。主治温毒发斑，血热吐衄，目赤肿痛，痈肿疮疡，肝郁胁痛，经闭痛经，癥瘕腹痛，跌打损伤。
红藤：别名大血藤，为木通科植物大血藤的茎。其性味苦平，归大肠经，能清热解毒，祛风活血止痛，消瘀散结，杀虫，利尿通淋，可治疗肠痈腹痛、热毒疮疡、跌打损伤、风湿痹痛、经闭痛经、绦虫、蛔虫等。
皂刺：别名皂角刺，辛，温。归肝、胃经。消肿托毒，排脓，杀虫，用于痈疽初起或脓成不溃；外治疥癣麻风。
藤梨根：酸、涩,凉。清热解毒，清热利湿，防肿瘤抗癌，祛风除湿，利尿止血，解毒消肿，消化不良、呕吐、风湿痹痛、风湿骨痛、消化道癌肿、消化道肿瘤、痈疡疮疖、风湿骨痛及黄疸等症。
中医学认为大肠息肉属于“癥瘕”“肠蕈”“肠中”“积聚”“脏毒”等范畴。最早见于《灵枢·水胀篇》：“肠蕈何如？寒气客于肠外，与卫气相搏，气不得荣，因有所系，癖而内着，恶气乃起，息肉乃生，其始生者，大如鸡卵。”其与先天禀赋不足、正气内虚、感受外邪、饮食不节或七情不和、损伤脾胃等因素相关。脾失健运、肝郁气滞，继而经脉阻滞、气机不利、痰湿瘀血内生，壅滞肠道。故湿热、寒湿、湿浊、痰浊、瘀血是病因。治疗重在活血祛瘀，化痰散结。治疗应遵循非破不行，非温不化，非行不散的原则。
本发明的选方中桂枝味辛甘性温，温通经脉而行瘀滞为君药。桃仁味苦甘平，活血化瘀，助君药以化瘀；丹皮味苦性微寒，散血祛瘀，清退瘀热；芍药味酸性微寒，养血和血，三者共为臣药；茯苓甘淡性平，健脾利湿，以助消徵之力为佐药；佐药黄连、红藤、薏苡仁清热燥湿；佐药皂角刺消肿排脓、佐药藤梨根清热消肿。全方配伍合理，立法周全，用药周到，具有活血化瘀，清热燥湿，和血消肿之功。
现代药理研究认为，桂枝具有扩张血管、抑制组胺、镇痛抗菌之效，茯苓可镇静、抑菌，牡丹皮有抑制血小板凝聚及抗炎、解热作用，赤芍有解痉、镇痛、抗炎作用，桃仁有显著抑制血凝作用。诸药合用，可降低血液黏稠度，避免血小板聚集，促进纤维蛋白溶解，从而改善肠道及肠周围微循环，改善腹部不适、腹痛、腹胀、排便异常等诸症状疗效俱佳。
采用本申请的中医组合物不仅可以预防息肉的复发还能通过调整、逆转患者整体病态因素，使患者恢复健康体质，增强抗病能力；经临床观察，大肠息肉术后服用本申请的中药组合物可缓解症状、预防复发，疗效显著，且无明显副作用，具有良好的临床应用价值。
实施例1
一种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝10g、茯苓20g、牡丹皮5g、炒桃仁15g、赤芍10g、黄连6g、皂刺10g、红藤20g、藤梨根10g和炒薏苡仁20g。
实施例2
一种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝20g、茯苓10g、牡丹皮15g、炒桃仁5g、赤芍30g、黄连2g、皂刺20g、红藤10g、藤梨根20g和炒薏苡仁10g。
实施例3
一种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝12g、茯苓18g、牡丹皮7g、炒桃仁13g、赤芍15g、黄连5g、皂刺12g、红藤18g、藤梨根12g和炒薏苡仁18g。
实施例4
一种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝18g、茯苓12g、牡丹皮13g、炒桃仁7g、赤芍25g、黄连3g、皂刺18g、红藤12g、藤梨根18g和炒薏苡仁12g。
实施例5
一种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝14g、茯苓16g、牡丹皮9g、炒桃仁11g、赤芍18g、黄连5g、皂刺14g、红藤16g、藤梨根14g和炒薏苡仁16g。
实施例6
一种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝16g、茯苓14g、牡丹皮11g、炒桃仁9g、赤芍22g、黄连3g、皂刺16g、红藤14g、藤梨根16g和炒薏苡仁14g。
实施例7
一种预防术后肠息肉复发的中药组合物，所述组合物包括以下组分：桂枝15g、茯苓15g、牡丹皮10g、炒桃仁10g、赤芍20g、黄连4g、皂刺15g、红藤15g、藤梨根15g和炒薏苡仁15g。
实施例8
实施例1-7的中药组合物可以直接煎服，也可以加入药学上可接受的辅料，如矫味剂、粘合剂、溶剂、润滑剂等制备成散剂、颗粒剂、丸剂、片剂、胶囊剂。
实验例
实验地点：陕西中医药大学附属医院
1.1临床资料
本组研究对象为64例大肠息肉术后患者，均为2015年1月-2020年3月在陕西中医药大学附属医院专家门诊及普通门诊的治疗者，经肠镜检查确诊为大肠息肉并行肠镜下息肉电凝电切治疗术。遵循患者就诊的次序随机进行分组，分为治疗组和对照组。治疗组32例，男17例，女15例；年龄27～61岁。对照组32例，男18例，女14例；年龄29～62岁。两组患者在性别、年龄以及临床病症表现方面均无明显差异(P>0.05)，具有可比性。
1.2纳入标准
所有纳入者为因各种腹部症状如腹胀腹痛、腹泻、便秘、腹部不适等诸症行肠镜检查确诊为大肠息肉并行大肠息肉电凝电切术的患者。且血、尿、粪三大常规及粪便细菌培养、血糖、肝功能、肾功能、腹部B超检查均无异常。如服用华法林、阿司匹林、氯吡格雷以及活血中成药等抗凝药物者术前停用药物1周以上，签署知情同意并坚持治疗及随访。
1.3排除标准
心、肝、肾等脏器器官严重障碍，恶性血液系统疾病，精神障碍，对所用药物有禁忌，不愿意参与本研究者。
1.4中医证候量化分级
主要症状观察的项目参考《中药新药临床研究指导原则》及《中医消化病诊疗方案》来制定，依据患者的主要症状、体征轻重程度来进行记分：依次记录为无、轻、中、重度四个等级，并分别记录0、2、4、6分。
如下表：
表1中医证候量化分级表
2方法
2.1治疗组
大肠息肉电凝电切术后给予常规补液、对症治疗，禁食1-2日后给予本申请实施例7的中药组合物，水煎服，熬得药液约300ml，分早晚2次于饭后1h服。1个月为1疗程，连续治疗3个疗程。并于术后6个月、12个月复查肠镜。
2.2对照组
大肠息肉电凝电切术后给予常规补液、对症治疗，禁食1-2日后给予双歧杆菌乳杆菌三联活菌片(商品名金双歧，由万泽集团旗下内蒙古双奇药业股份有限公司生产，国药准字S19980004)，口服，2g/次，3次/日。1个月为1疗程，连续治疗3个疗程。并于术后6个月、12个月复查肠镜。
2.3疗效判定
预防大肠息肉复发的疗效参照《中医病证诊断疗效标准》拟定。“复发”定义为大肠息肉患者行内镜下切除治疗后并明确上一次息肉切除术时已经将所有息肉切除，其后再次行肠镜检查发现大肠息肉。
中医证候疗效参照《中药新药临床研究指导原则》。临床痊愈：症状、体征消失或基本消失，证候积分减少＞95％；显效：症状、体征明显有所改善，证候积分减少＞70％；有效：症状、体征均见到好转，证候积分减少＞30％；无效：症状、体征皆没有明显改善，甚至临床表现有所加重，证候积分减少不足30％。(注：证候积分计算公式(尼莫地平法)为：[(治疗前积分-治疗后积分)/治疗前积分]×100％。)
2.4统计学方法
统计分析采用SPSS 19.0软件，计量资料的比较用t检验；计数资料的比较用x2检验。P＜0.05为差异有统计学意义。
3结果
经过3个月的治疗后，临床症状及体征比较，治疗组共32例，其中9例临床痊愈，14例显效，8例有效，1例无效，总有效率为96.87％；对照组共32例，其中临床痊愈3例，显效为6例，有效为11例，无效为12例，总有效率为62.50％。两组经X2检验比较后，得出两组治疗有显著性差异(P<0.05)，见表2。
表2两组治疗前后临床症状及体征疗效比较
病历1：患者王某某，以“左下腹隐痛20余年”为主诉于2019年5月2日就诊。结肠镜检查示：升大肠息肉(已钳除)，见附图1，病理检查示：(升结肠)腺瘤性息肉。服用活血消肉通肠汤治疗90天后，上症消失。
11个月复查结肠镜示：直肠及全结肠未见异常，结肠镜检查结果见附图2。
以上所述仅为本发明的较佳实施例，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (6)
1.一种预防术后肠息肉复发的中药组合物，其特征在于，所述组合物包括以下组分：桂枝10-20份、茯苓10-20份、牡丹皮5-15份、炒桃仁5-15份、赤芍10-30份、黄连2-6份、皂刺10-20份、红藤10-20份、藤梨根10-20份和炒薏苡仁10-20份。
2.根据权利要求1所述的预防术后肠息肉复发的中药组合物，其特征在于，所述组合物包括以下组分：桂枝12-18份、茯苓12-18份、牡丹皮7-13份、炒桃仁7-13份、赤芍15-25份、黄连3-5份、皂刺12-18份、红藤12-18份、藤梨根12-18份和炒薏苡仁12-18份。
3.根据权利要求1所述的预防术后肠息肉复发的中药组合物，其特征在于，所述组合物包括以下组分：桂枝14-16份、茯苓14-16份、牡丹皮9-11份、炒桃仁9-11份、赤芍18-22份、黄连3-5份、皂刺14-16份、红藤14-16份、藤梨根14-16份和炒薏苡仁14-16份。
4.根据权利要求1所述的预防术后肠息肉复发的中药组合物，其特征在于，所述组合物包括以下组分：桂枝15份、茯苓15份、牡丹皮10份、炒桃仁10份、赤芍20份、黄连4份、皂刺15份、红藤15份、藤梨根15份和炒薏苡仁15份。
5.一种预防术后肠息肉复发的中药制剂，其特征在于，包括权利要求1-4任一所述的中药组合物和药学上可接受的辅料。
6.根据权要求5所述的中药制剂，其特征在于，所述剂型为散剂、颗粒剂、丸剂、片剂或胶囊剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010476786.XA CN111529640A (zh) | 2020-05-29 | 2020-05-29 | 一种预防术后肠息肉复发的中药组合物和中药制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010476786.XA CN111529640A (zh) | 2020-05-29 | 2020-05-29 | 一种预防术后肠息肉复发的中药组合物和中药制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111529640A true CN111529640A (zh) | 2020-08-14 |
Family
ID=71969899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010476786.XA Pending CN111529640A (zh) | 2020-05-29 | 2020-05-29 | 一种预防术后肠息肉复发的中药组合物和中药制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111529640A (zh) |
-
2020
- 2020-05-29 CN CN202010476786.XA patent/CN111529640A/zh active Pending
Non-Patent Citations (1)
| Title |
|---|
| 穆云等: "大肠息肉电凝电切术后应用桂枝茯苓丸加减临床分析", 《实用中医药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106361993B (zh) | 一种防治胃黏膜损伤的药物组合物及其制备方法 | |
| WO2005056029A1 (fr) | Preparation de medecine traditionnelle chinoise pour le traitement d'une tumeur et procede de production et d'utilisation de cette preparation | |
| CN108542941A (zh) | 一种治疗上皮内瘤变的中药组合物及其制备方法 | |
| CN111529640A (zh) | 一种预防术后肠息肉复发的中药组合物和中药制剂 | |
| CN113769002B (zh) | 一种治疗疣状胃炎的中药汤 | |
| CN110772568A (zh) | 一种治疗放射性肠炎的中药组合物及其制备方法 | |
| CN114903960B (zh) | 一种治疗慢性胃炎的中药组合物及其制备方法 | |
| CN105232991B (zh) | 一种治疗胃黏膜损伤的药物组合物 | |
| CN108619427A (zh) | 一种预防治疗痛风性关节炎的祛痛降酸药茶 | |
| CN113925952B (zh) | 一种中药组合物在制备防治消化道肿瘤药物中的应用 | |
| CN113633748B (zh) | 治疗肝硬化自发性细菌性腹膜炎湿热瘀结证的药物及其制备方法 | |
| CN116370596B (zh) | 一种治疗胆道疾病疾病的中药组合物 | |
| CN115040576B (zh) | 一种治疗急性胰腺炎的药物组合物 | |
| CN102872344B (zh) | 治疗溃疡性结肠炎的中药灌肠颗粒剂及其制备方法 | |
| CN107875189B (zh) | 一种治疗上消化道出血的药物组合物及其制备方法 | |
| CN107913402A (zh) | 一种治疗萎缩性胃炎的中西医结合药物及制备方法 | |
| CN1088378C (zh) | 治疗慢性浅表性胃炎的中药口服液及其制备方法 | |
| CN116392558A (zh) | 一种治疗腺瘤性大肠息肉的中药组合物及其应用 | |
| CN113908212A (zh) | 一种治疗非甾体抗炎药致小肠黏膜损伤的中药组合物、制备方法及其制剂 | |
| CN106491974B (zh) | 一种治疗肠麻痹的中药组合物及中药汤剂 | |
| CN106177347A (zh) | 一种治疗便秘的药物组合物 | |
| CN117338879A (zh) | 一种用于溃疡性结肠炎的中药制剂及其应用 | |
| CN104888140A (zh) | 一种治疗风热蕴肤型玫瑰糠疹的中药制剂及其制备方法 | |
| CN117883536A (zh) | 一种用于治疗肠道炎癌转化类疾病的中药组合物及其应用 | |
| CN118178588A (zh) | 预防大肠腺瘤内镜治疗术后复发的中药组合物及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200814 |